SUMMARY The results of a 12-month blind randomised trial comparing the intraocular pressure lowering effect of timolol 0 25% with timolol 05% are presented. 27% In addition it has no intrinsic sympathomimetic or local anaesthetic activity.4
In addition it has no intrinsic sympathomimetic or local anaesthetic activity. 4 Timolol appears to lower intraocular pressure by decreasing aqueous production rather than by increasing aqueous outflow. A reduction in aqueous inflow of 13-48% has been demonstrated by fluorophotometry. 5 Several short-tern studies undertaken to investigate the ocular hypotensive effect of various concentrations of topical timolol have indicated that the lowering of intraocular pressure may be maximal at a concentration of timolol 0 25%.367 In a significant number of patients receiving continuous topical timolol therapy a gradual reduction in the efficacy of timolol (with regard to lowering of intraocular pressure) appears with time (often called 'long-term drift').
This study was undertaken to investigate 2 particular parameters of the therapeutic effect of timolol in open-angle glaucoma. The study attempts to establish the reduction in intraocular pressure which is produced and sustained by the 2 commercially Correspondence to Mr K. B. Mills. FRCSEd. available concentrations of timolol solution (namely, 0 25% and 0 5%) and whether there is a statistically significant difference between the 2 concentrations, when the reduction in intraocular pressure is compared, after continuous long-term topical instillation. Secondly, this study attempts to provide further information on the incidence and importance of the phenomenon of long-term drift. Blind randomised non-crossover long-term trial comparing topical timolol 025% with timolol 05% Although regular follow-up (in accordance with the trial criteria) was maintained for such patients, subsequent recordings of intraocular pressure were not used in the statistical analysis. Any serious ocular or systemic side effects were noted at each visit. The code (which was held in the Pharmacy Department) was broken only when all patients had completed a 12-month follow-up.
Materials and methods

Patients
Results
Of the 15 patients who instilled timolol 0 25% 9 were male, 6 female, and their mean age was 71 years. Of the 15 who received timolol 05% 6 were male, 9 female, and their mean age was 69 years.
In one patient the intraocular pressure rose immediately after timolol 0O25% instillation, which was therefore discontinued. Only 14 continued to instil timolol 0 25%-that is, no replacement was included.
Eight (27%) patients (13 eyes, or 22%) in whom the intraocular pressure was initially controlled following timolol instillation required further antiglaucoma therapy to maintain control (see Table  1 ). Five were receiving timolol 05% and 3 timolol 025% (not significant). Seven of these eyes had an intraocular pressure greater than 22 mmHg at both the 3-month and 6-month follow-up periods and additional antiglaucoma medication was begun at 6 months (in accordance with the trial criteria).
The mean pretreatment and follow-up intraocular pressures for eyes treated with timolol 025% and timolol 0O5% are shown in Table 3 . Statistical analysis (Student t test) of these reductions in intraocular pressure comparing timolol 025% with timolol 05% instilled into right eyes or left eyes showed little significance. Where statistically significant differences existed they always favoured timolol 0O25% (Table 3) .
Side effects were few. One patient complained of occasional hallucinations, and 2 patients complained of tinnitus (likened to egg-shell in the ear) which was temporary. The mean intraocular pressure values refer to eyes treated with timolol 0-25% and timolol 0-5% only. Although no additional antiglaucoma medication was instituted before 6 months, intraocular pressure levels were raised (i.e., >22 mmHg) in 7 eyes at the 3-month stage (in accordance with the trial criteria). It is important to maintain frequent and regular follow-up for all patients receiving topical timolol, as a significant number will show a reduction in its effect with time which may continue past the 12-month stage (but was not investigated in this trial).
In those patients (70%) in whom the reduction in intraocular pressure was sustained throughout the trial period there is little clinical significance in the fall of intraocular pressure produced by either timolol 0 25% or timolol 0 5%. Many studies have shown a reduction in intraocular pressure from pretreatment values of 25-30% with a range of 21-46% 37 15-17 The lack of statistical significance in intraocular pressure reduction when timolol 0 25% is compared with timolol 0-5% has been recorded in previous studies (although not specifically commented upon). Obstbaum et al.3 demonstrated a reduction of 7-5 mmHg (29-2% of the pretreatment intraocular pressure) after 3 months of topical timolol 0-25% as compared with a reduction of 7-8 mmHg (27-3% of pretreatment intraocular pressure) with timolol 0 5% over an identical time period. Radius et al.7 reported a reduction in intraocular pressure of 8 mmHg (26% of pretreatment value) with topical timolol 0-25% as compared with a reduction of 7-0 mmHg (22% of pretreatment value) with timolol 0 5% after one week's therapy. This longer-term study confirms this trend.
Single-dose studies with various concentrations of topical timolol (0.1%, 0-25%, 0 5% and 1-0%) have suggested that a maximum ocular hypotensive effect is achieved with timolol 0.5%. 8 However, if one accepts the fact that the percentage fall in intraocular pressure is a function of the initial intraocular pressure (and in the last study'8 the pretreatment mean intraocular pressures of each treatment group were markedly dissimilar, with the group receiving timolol 0-5% having the highest pretreatment mean intraocular pressure), then the reported results'8 become less meaningful and do not necessarily contradict the results reported here.
The results presented in this paper suggest little difference in effectiveness between long-term topical timolol 0 25% and timolol 05%. This suggests that timolol 0-25% should be the initial treatment of choice, and if this proves ineffective (either early or late) then alternative or additive therapy should be considered in preference to the common clinical practice of changing the concentration of timolol to 0-5%. In addition this report confirms the existence and importance of long-term drift (or loss of control with continuous long-term topical timolol).
Timolol continues to have an important role in the medical management of open-angle glaucoma. As further experience with its use accumulates its limitations will become more apparent.
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